Compare EOG Resources Inc (EOG) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Gilead Sciences, Inc. — how do they compare? EOG Resources Inc trades at $148.57 (market cap $75.64B), while Gilead Sciences, Inc. trades at $147 (market cap $182.09B). The key difference: Gilead Sciences, Inc. is far larger — about 2.4× EOG Resources Inc's market cap, and EOG Resources Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Gilead Sciences, Inc. for 111 Days on average.
| EOG | GILD | |
|---|---|---|
Market Cap | $75.64B | $182.09B |
Volume | 2,041,336 | 4,960,247 |
Sector | Energy | Health |
52-Week High | $153.74 | $155.80 |
52-Week Low | $101.78 | $116.74 |
Typical Hold Time | 59 Days | 111 Days |
Enterprise Value | $78.99B | $205.15B |
Dividend Yield | 2.83% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $148.51, up 2.93% today, with a bullish technical signal from moving averages and strong fundamental metrics including a P/E of 11.22 and net income margin of 25.81%. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.07 exceeding expectations. Recent news highlights robust operational execution and disciplined capital allocation, with a CFO transition announced in September 2026.
Outlook remains positive with a consensus price target of $164.77, offering ~11% upside. Key opportunities include 5% oil volume growth guidance and strong free cash flow generation. Risks involve oil price volatility, as seen in recent price retreats, and execution of leadership transition. The stock presents a compelling value with no sell ratings among 66 analysts.
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
